NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk (NYSE: NVO) stock slipped 1.7% through 12:10 a.m. ET Monday on a pair of news items with which investors seem ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...

We recently published a list of 10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil. In this article, we are going ...

Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) and reminds investors of the ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a strong-buy rating to a buy rating in a ...